Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates
Citations Over TimeTop 1% of 2017 papers
Abstract
Sulfoximines have gained considerable recognition as an important structural motif in drug discovery of late. In particular, the clinical kinase inhibitors for the treatment of cancer, roniciclib (pan-CDK inhibitor), BAY 1143572 (P-TEFb inhibitor), and AZD 6738 (ATR inhibitor), have recently drawn considerable attention. Whilst the interest in this underrepresented functional group in drug discovery is clearly on the rise, there remains an incomplete understanding of the medicinal-chemistry-relevant properties of sulfoximines. Herein we report the synthesis and in vitro characterization of a variety of sulfoximine analogues of marketed drugs and advanced clinical candidates to gain a better understanding of this neglected functional group and its potential in drug discovery.
Related Papers
- → Accelerated drug discovery by rapid candidate drug identification(2019)34 cited
- → Biochemical marker discovery, testing and evaluation for facilitating OA drug discovery and development(2017)25 cited
- → Whole-animal cellular and molecular imaging to accelerate drug development(2002)97 cited
- → Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development(2003)32 cited
- → Minimizing the Potential for Drug Bioactivation of Drug Candidates to Success in Clinical Development(2010)